CURRENT REPORT 29/2023
June 13th, 2023

Recommendation of Ryvu's project for funding by the Medical Research Agency

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on June 13th, 2023 it became aware of the placement of the Company's project titled "Conducting a multicenter, open-label Phase II clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior venetoclax and hypomethylating agent therapy" ("Project") on the ranked list of projects recommended for funding under the competition for the development of targeted or personalized medicine based on nucleic acid-based medicinal products and small molecule compounds organized by the Medical Research Agency (in Polish: Agencja Badań Medycznych, "MRA").

The RIVER-81 study ("Study") is an important component of the "Development Plans for 2022-2024" ("Development Plans"), which the Company announced in the current report 16/2022 on August 19th, 2022. The expansion of clinical development in AML/HR-MDS (Acute Myeloid Leukaemia / High-Risk Myelodysplastic Syndrome) area through the initiation of Phase II clinical trials for RVU120 in combination therapy, is part of the planned broad clinical development of RVU120 in multiple indications (hematology and solid tumors) and in various therapeutic settings (both monotherapy and combination therapy), aiming at maximizing the potential of RVU120 and diversifying the risks associated with clinical development. The initiation of the Phase II clinical trials in both hematology and solid tumor indications is planned for the second half of 2023.

The objective of the Project is to conduct a multicenter, open-label Phase II clinical trial evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with AML or HR-MDS who have failed prior therapy with venetoclax and a hypomethylating agent.

The Project received the highest number of ranking points among all submitted applications.

- the total net value of the Project is: PLN 133,915,538.70.

- recommended amount of the funding: PLN 62,268,848.90;

- assumed Project implementation period: 48 months.

In case the funding agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's own funds.

RVU120 is a clinical-stage, selective, first-in-class dual inhibitor of CDK8 and CDK19 kinases. RVU120 has demonstrated efficacy in a number of solid tumors and hematologic malignancies in in vitro and in vivo models. In addition, RVU120 has shown early signs of clinical activity in treated patients. Two

clinical trials of RVU120 dose escalation phase are currently underway in patients: (i) with AML/HR-MDS and (ii) with solid tumors.

Venetoclax is a BCL-2 inhibitor that is approved in combination with a hypomethylating agent for the treatment of newly diagnosed AML in patients that are unfit to receive intensive induction chemotherapy. Its use has been widely adopted in the treatment paradigm. In the non-clinical studies, RVU120 was synergistic with venetoclax in both venetoclax-sensitive and venetoclax-resistant models. In the opinion of the Company's Management Board, these data combined with a biologic rationale provide strong basis to investigate this combination in the proposed clinical trial.

The Company will announce the conclusion of the relevant funding agreement with MRA, as well as other significant events related to the Project, in the form of current reports.

Legal basis: Article 17.1 of MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board